Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Opus Genetics Inc (IRD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.00-6.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IRD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital allocation effectively through private placements and debt | A supporting condition in Opus Genetics Inc's published investment case. The stated target is No excessive dilution or debt beyond current levels through FY 2027. | Under Pressure | Capital raises cause >20% dilution or debt increases materially beyond current levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IRD is speculative clinical-stage growth, not a proven compounder: its programs are advancing, but revenue is limited and the company is loss-making. The thesis state is watch, with the signal recently shifting from cautious to mixed; confidence in the evidence is medium.
The valuation evidence points to a premium versus peers, while the expectations gap is negative and model confidence is low. The market appears to be assigning value to future program potential, but the evidence does not show broad financial delivery; the priced-in assessment is tagged justified, with no fragility gates triggered.
Near term, results may remain uneven: the company reported lower revenue and a larger operating loss in 2026-Q2, while R&D spending rose. Clinical execution has progressed, with LCA5 and BEST1 Cohort 1 enrollment completed and LCA5 dosing planned for the fourth quarter of 2026; management says resources should fund operations into 2029, though that remains an estimate.
The multi-year thesis hinges on advancing gene-therapy programs toward meaningful clinical milestones while managing cash use. Near term, a guidance cut or further weakening in jobs data could add pressure, while stronger results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, IRD remains a high-risk clinical-development story with a stated runway and visible trial progress, but weak financial performance and elevated miss risk leave execution as the central test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Improve earnings performance and reduce net losses | A primary condition in Opus Genetics Inc's published investment case. The stated target is Net loss improves from -$65.5M in 2026-Q1 to less negative by FY 2027. | Broken | Net losses worsen or remain flat beyond FY 2027 | Net income: $-8.098M FY2026-Q2; GAAP. Published target: Net loss improves from -$65.5M in 2026-Q1 to less negative by FY 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-8,098,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Secure funding to sustain operations into H2 2027 | The company aims to secure funding into H2 2027. | Intact | Failure to secure funding covering operations beyond H2 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve and sustain revenue growth near analyst expectations | A supporting condition in Opus Genetics Inc's published investment case. The stated target is >=15% revenue growth YoY. | Improving | Revenue growth falls below 10% YoY in FY 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.76 → $-0.70 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-25 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-26 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-27 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-28 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-29 | $-0.76 | $15,233,200 | 11 / 13 |
| 2026-07-30 | $-0.76 | $14,830,940 | 11 / 16 |
| 2026-07-31 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-01 | $-0.76 | $15,006,125 | 12 / 13 |
| 2026-08-02 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-03 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-04 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-05 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-06 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-07 | $-0.75 | $14,123,412 | 12 / 13 |
| 2026-08-08 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-09 | $-0.77 | $14,640,880 | 12 / 17 |
| 2026-08-10 | $-0.75 | $14,123,412 | 12 / 13 |
| 2026-08-12 | $-0.75 | $14,123,412 | 12 / 13 |
| 2026-08-13 | $-0.75 | $14,123,412 | 12 / 13 |
| 2026-08-14 | $-0.75 | $14,123,412 | 12 / 13 |
| 2026-08-15 | $-0.75 | $14,123,412 | 13 / 14 |
| 2026-08-16 | $-0.75 | $14,123,412 | 13 / 14 |
| 2026-08-17 | $-0.75 | $14,123,412 | 13 / 14 |
| 2026-08-18 | $-0.75 | $14,123,412 | 13 / 14 |
| 2026-08-19 | $-0.75 | $14,123,412 | 13 / 14 |
| 2026-08-20 | $-0.70 | $14,089,063 | 13 / 14 |
| 2026-08-21 | $-0.70 | $13,361,667 | 13 / 14 |
| 2026-08-22 | $-0.70 | $13,363,000 | 13 / 14 |
| 2026-08-23 | $-0.70 | $13,363,000 | 13 / 14 |
| 2026-08-24 | $-0.70 | $13,363,000 | 13 / 14 |
| 2026-08-25 | $-0.70 | $13,363,000 | 12 / 13 |
| 2026-08-26 | $-0.70 | $13,363,000 | 12 / 13 |
| 2026-08-27 | $-0.70 | $13,363,000 | 12 / 13 |
| 2026-08-28 | $-0.70 | $13,363,000 | 12 / 13 |
| 2026-08-29 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-08-30 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-08-31 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-01 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-02 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-03 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-04 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-05 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-06 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-07 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-08 | $-0.71 | $12,696,333 | 12 / 13 |
| 2026-09-09 | $-0.71 | $12,699,067 | 12 / 13 |
| 2026-09-10 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-11 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-12 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-13 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-14 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-15 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-16 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-17 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-18 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-19 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-20 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-21 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-22 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-23 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-24 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-25 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-26 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-27 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-28 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-29 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-09-30 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-01 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-02 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-03 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-04 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-05 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-06 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-07 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-08 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-09 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-10 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-11 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-12 | $-0.70 | $11,905,375 | 12 / 13 |
| 2026-10-13 | $-0.70 | $11,906,625 | 12 / 13 |
| 2026-10-14 | $-0.70 | $11,906,625 | 12 / 13 |
| 2026-10-15 | $-0.70 | $11,906,625 | 12 / 13 |
| 2026-10-16 | $-0.70 | $11,906,625 | 12 / 13 |
| 2026-10-17 | $-0.70 | $11,906,625 | 12 / 13 |
| 2026-10-18 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-19 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-20 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-21 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-22 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-23 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-24 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-25 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-26 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-27 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-28 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-29 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-30 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-10-31 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-11-01 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-11-02 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-11-03 | $-0.70 | $11,937,875 | 12 / 13 |
| 2026-11-04 | $-0.70 | $11,937,875 | 12 / 13 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 18 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.